Core Viewpoint - Yuexiu Services (06626.HK) reported its interim results for the first half of 2025, showing a total revenue of RMB 1.962 billion, with significant contributions from both non-commercial and commercial property management services [1] Financial Performance - Total revenue for the first half of 2025 was RMB 1.962 billion [1] - Revenue from non-commercial property management and value-added services amounted to RMB 1.5919 billion [1] - Revenue from commercial property management and operation services was RMB 369.9 million [1] - Gross profit margin stood at 21.3% [1] - Profit attributable to owners of the company reached RMB 239.7 million [1] Dividend Information - The board proposed an interim dividend of HKD 0.088 per share, equivalent to RMB 0.08 per share [1] - The dividend payout ratio is set at 50% [1] Operational Metrics - As of June 30, 2025, the total managed area was 72.3 million square meters [1] - The contracted area reached 92.5 million square meters [1]

（股份代號：06626） 截至二○二五年六月三十日止六個月的 中期業績公告 截至二○二五年六月三十日止六個月業績摘要 (ii) 自商業物業管理及運營服務所得收入為人民幣369.9百萬元。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （在香港註冊成立的有限公司） – 1 – ‧ 總收入為人民幣1,961.9百萬元，其中： (i) 自非商業物業管理及增值服務所得收入為人民幣1,591.9百萬元；及 ‧ 截至二○二五年六月三十日，本集團在管面積為72.3百萬平方米，合約面積 為92.5百萬平方米。 ‧ 毛利率為21.3%。 ‧ 本公司擁有人應佔盈利為人民幣239.7百萬元。 ‧ 董事會建議宣派二○二五年中期股息每股0.088港元（相當於每股人民幣0.080 元），派息率為50%。 中期業績 越秀服務集團有限公司（「本公司」，及其附屬公司，「本集團」）董事（「董事」）會（「董 事會」）謹此宣佈本集團截至二○二五年六月三十日止六個月（「本期間」）的未經審核 ...

ck Code : 1093) 2025 Interim Results Presentation Aug. 2025 ININI China's Leading Innovative Pharmaceutical Enterprise R&D Capabilities 00 5 capacity of 250,000L R&D centers located in R&D platforms China & the U.S. 201010 + - 2401 Innovative drugs and R&D professionals new formulations Manufacturing Capabilities Commercialization Capabilities 2 10+ Production bases for pharmaceutical products Nano formulation production capacity of 20M doses/year; Biologics fermentation Chemical drugs production capacity o ...

格隆汇8月11日丨越秀服务(06626.HK)发布公告，公司将于2025年8月21日召开董事会会议，藉以审议并 批准包括截至2025年6月30日止的六个月期间的未经审核中期业绩，及考虑宣派中期股息（如有）。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 承董事會命 越秀服務集團有限公司 余達峯 公司秘書 香港，二○二五年八月十一日 （於香港註冊成立的有限公司） （股份代號：06626） 董事會會議日期 越秀服務集團有限公司（「本公司」及其附屬公司「本集團」）董事（「董事」）會（「董事 會」）宣佈，二○二五年八月二十一日（星期四）將舉行董事會會議，以批准本集團截 至二○二五年六月三十日止六個月中期業績以及考慮派付中期股息（如有）及其他事 項。 於本公告刊發日期，董事會成員包括： 獨立非執行董事： 洪誠明、許麗君及梁耀文 執行董事： 王建輝、張成皓及張勁 非執行董事： 江国雄（主席）、張建国及楊昭煊 ...

第 2 頁 共 10 頁 v 1.1.1 III.已發行股份及/或庫存股份變動詳情 第 1 頁 共 10 頁 v 1.1.1 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06626 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,502,212,177 | | | | 1,502,212,177 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 1,502,212,177 | | 0 | | 1,502,212,177 | | 截至月份: | 2025年7月31日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及 ...

Investment Rating - The report maintains a "Positive" investment rating for the healthcare industry [9]. Core Insights - Chinese pharmaceutical companies are increasingly enhancing their original research capabilities, leading to a surge in high-quality innovative products gaining international recognition. This trend is facilitating the acceleration of domestic innovative drugs entering global markets through two primary pathways: "building ships" and "borrowing ships" [2][6]. - The total value of license-out transactions from China reached over $43 billion in 2024, accounting for nearly 20% of the global total, indicating a significant shift in the global pharmaceutical landscape as Chinese innovative drugs gain traction [6][17]. Summary by Sections Innovative Drug Globalization - Chinese innovative drug companies are transitioning from "following overseas" to "independent innovation," with a notable increase in original research capabilities. The number of Chinese companies participating in major international conferences like AACR and ASCO has reached historical highs, with 126 companies presenting nearly 300 new drug research results at the 2025 AACR conference [17][18]. - The number of original innovative drugs approved in China has increased from 11 in 2015 to 92 in 2024, with the proportion of globally developed first-in-class (FIC) drugs rising from 9% to 24% during the same period [21][22]. "Building Ships" and "Borrowing Ships" Models - "Building ships" refers to domestic companies independently conducting overseas clinical trials and obtaining market approvals. Notable examples include BeiGene's BTK inhibitor, which achieved over $2.6 billion in global sales, and Legend Biotech's CAR-T therapy, which reached $963 million in global sales in 2024 [25][26]. - "Borrowing ships" involves leveraging partnerships for international development and commercialization. The total value of license-out transactions in the Chinese innovative drug sector reached $51.9 billion in 2024, with over 50 transactions reported in the first half of 2025, totaling $48.4 billion [27][28]. Investment Perspective - The report emphasizes that the ongoing transformation in the healthcare sector, driven by innovative drug globalization, presents significant investment opportunities. Companies with strong cash flow, innovative capabilities, and established research platforms are particularly well-positioned for growth [43].

Investment Rating - The report maintains a "Positive" investment rating for the property management industry [13]. Core Insights - The property management sector is experiencing stable growth in management scale, with a focus on improving quality and efficiency, leading to a recovery in profitability. High-quality property management companies are expected to achieve long-term stable performance and even maintain certain growth rates [4][11]. - The transition from "profitable revenue" to "cash flow profit" is underway, with many companies demonstrating strong cash flow performance due to effective receivables management [9][60]. - There is an increasing emphasis on shareholder returns, with a rising proportion of dividends and share buybacks, resulting in an average total return rate exceeding 6% for mainstream property management companies [10][11]. Summary by Sections Profit Stability of Property Management Companies - The stability of profits is fundamental to exploring the dividend value of property management companies. After over three years of adjustments, companies are increasingly focusing on core operations, with many achieving stable or even growing profits [8][24]. - The management scale remains stable, with many companies emphasizing market expansion capabilities. Some have begun to recover gross and net profit margins through quality improvements [25][38]. Transition from Profit to Cash Flow - Most property management companies maintain a cash flow coverage ratio of over 1X against net profit, indicating a smooth transition to cash flow profits. However, some companies face challenges due to receivables and impairment issues [9][60]. - The differentiation in receivables and cash collection capabilities is a key factor affecting the cash profit ratio among companies [9][60]. Dividend Potential and Excess Cash - Property management companies are increasingly focusing on higher dividend payouts to reward shareholders, with an average dividend payout ratio of over 50% expected in 2024. The average dividend yield for mainstream companies is projected to reach 5.5% [10][11]. - Many companies have significant cash reserves, with some exceeding 10 billion yuan, indicating potential for higher future dividends [10][11]. Industry and Company Valuation - The report suggests that the dividend value is just the starting point for investment in high-quality state-owned and private property management companies. The potential for cash distribution and value-added services is seen as hidden options for future growth [11][12]. - The report recommends focusing on three main lines: companies expected to maintain high growth rates, those with superior growth and static dividend returns, and undervalued state-owned enterprises with excess cash [11].

Group 1 - Recent leadership changes at Yuexiu Services and Yuexiu Real Estate Fund, with Jiang Guoxiong appointed as the new president and chairman for both companies [1][2] - Jiang Guoxiong has a strong background in the company, having served in various leadership roles since 2020, contributing to significant sales growth in the central and western regions [2][3] - The appointment of Jiang Guoxiong signals a strategic move to consolidate leadership and address performance challenges faced by both entities [1][4] Group 2 - Yuexiu Services reported total revenue of 3.868 billion yuan in 2024, a 20% increase year-on-year, but net profit decreased by 27.5% to 353 million yuan due to a 237 million yuan goodwill impairment [4][5] - Yuexiu Real Estate Fund experienced a total revenue of 2.032 billion yuan in 2024, a decline of 2.7%, with a significant after-tax loss of approximately 340 million yuan, worsening from a loss of 3.955 million yuan in 2023 [5] - Jiang Guoxiong faces the challenge of reversing the declining net profit of Yuexiu Services and helping Yuexiu Real Estate Fund return to profitability amid current market conditions [5]

Core Viewpoint - The new management team at Yuexiu Property faces the challenge of revitalizing the commercial sector, which has been underperforming due to market downturns [1][6]. Management Changes - Yuexiu Property announced the appointment of Jiang Guoxiong as the new chairman for both Yuexiu Services and Yuexiu REIT, replacing Lin Deliang and Zhu Hu Song respectively [2][4]. - Jiang Guoxiong has a rapid career progression within Yuexiu, having held various leadership roles since November 2020, including positions in the Central and Southwest regions [2][3]. Performance Overview - Yuexiu REIT reported a total revenue of 2.032 billion yuan in 2024, a decrease of 2.7% year-on-year, primarily due to a decline in office property income [5]. - The office income for Yuexiu REIT was 1.15 billion yuan, accounting for 56.6% of total revenue, and saw a year-on-year decline of 4.5% [5]. - Yuexiu Services experienced a total revenue of 3.868 billion yuan, reflecting a 20% increase year-on-year, but net profit fell by 27.5% to 353 million yuan due to a significant goodwill impairment [5]. Future Challenges - The overall real estate market remains under pressure, and the commercial and property sectors have not yet shown signs of recovery, presenting a significant challenge for Jiang Guoxiong in leading Yuexiu's commercial segment out of its current low performance [6].